An observational study in Primary Aldosteronism, Adrenal Cushing Syndrome and Pheochromocytoma, sponsored by Helsinki University Central Hospital. Active, not recruiting at 1 site in Finland. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Helsinki University Central Hospital · Observational
Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the exact underlying cause remains obscure in many adults who face sudden death outside heath care organizations. The investigators aim to find proof that primary aldosteronism is a risk factor for sudden death and to characterize the prevalence of adrenal pathology in sudden death of undetermined cause in a case-control study. In addition, the study aims to characterize the prevalence of other adrenal pathology i.e. silent adenomas, cortisol-producing adenomas and pheochromocytomas in sudden death. The investigators also seek evidence that other endocrine hormone overproduction-causing diseases are more prevalent in persons with sudden death compared with those experiencing traumatic or suicidal death sudden death.
201 studies on the registry are indexed under Hyperaldosteronism; 93 are open to participants now.
This study's planned enrollment of 400 is above the median of 200 across 103 observational studies indexed under Hyperaldosteronism.
Browse Hyperaldosteronism studies →Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
We enroll aproximately 200 consecutive patients with out-of-hospital, sudden death to both groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Consecutive patients with out-of-hospital, sudden death
Exclusion Criteria:
Unexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
Diagnostic Test: Adrenal aldosterone synthase (CYP11B2) staining · Diagnostic Test: Adrenal cortisol synthase (CYP11B1) staining · Diagnostic Test: Histopathological analysis
Death because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
Diagnostic Test: Adrenal aldosterone synthase (CYP11B2) staining · Diagnostic Test: Adrenal cortisol synthase (CYP11B1) staining · Diagnostic Test: Histopathological analysis
Immunoshistochemical diagnosis of primary aldosteronism
Immunoshistochemical diagnosis of adrenal hypercortisolism
Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
CYP11B2 staining in adrenal glands
Histopathological diagnosis of the autopsy
Time frame: Through study completion, an average of 2 years
CYP11B1 staining in adrenal glands
Histopathological diagnosis of the autopsy
Time frame: Through study completion, an average of 2 years
CYP11B2 staining in adrenal glands
Histopathological diagnosis of the autopsy
Time frame: Through study completion, an average of 2 years
Pheochromocytoma or paraganglioma
Histopathological diagnosis of the autopsy
Time frame: Through study completion, an average of 2 years
Neuroendocrine tumor
Histopathological diagnosis of the autopsy
Time frame: Through study completion, an average of 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Jan 2023, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helsinki University Central Hospital →